Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference… – Press Release - CayPress

Wednesday, May 18, 2022

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference… – Press Release


NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. INDP (“Indaptus” or the “Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 8:30am ET.

A live webcast of the presentation can be accessed on the Investors section of Indaptus’ website. A replay of the webcast will be archived and available following the event for approximately 90 days.

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in preclinical models. Tumor eradication by Indaptus technology has been demonstrated to produce both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a specific tumor antigen in pre-clinical models. Indaptus technology has also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models. Indaptus has carried out successful GMP manufacturing of its lead clinical oncology candidate,…



The post Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference… – Press Release appeared first on CaymanMama.com.



from CaymanMama.com https://ift.tt/D45IjRe

No comments:

Post a Comment